Key result
Diabetes is linked to ~4.5-fold higher odds of elevated hsCRP during ACS presentation.
Observational (n=93)
No
Approximately two-thirds of patients presenting with acute coronary syndrome have arrival hsCRP levels >2 mg/L, an elevation independently associated with diabetes and current smoking.
Answers are grounded in this paper and cite their sources.
Elevated hsCRP in ACS linked to diabetes and smoking supports inflammation assessment; leaves open whether targeted therapies improve outcomes in these patients.
BACKGROUND: High-sensitivity C-reactive protein (hsCRP) reflects systemic inflammation. The frequency of hsCRP >2 mg/L, a threshold used in anti-inflammatory trials, among patients presenting with acute coronary syndrome (ACS) is incompletely characterized. METHODS: We retrospectively analyzed consecutive patients presenting with ACS at Sismanoglio General Hospital of Athens between January 2023 and May 2024 who had hsCRP measured on arrival. We assessed the frequency and magnitude of hsCRP elevation, clinical and laboratory associations, and factors associated with hsCRP >2 mg/L after adjustment for age. RESULTS: Of 103 patients, 93 (90.3%) had hsCRP measured and were included (median age: 65 years; interquartile range: 58-73; 84.9% male). Elevated hsCRP (>2 mg/L) occurred in 67.7%, and 25.8% had hsCRP >10 mg/L. Median hsCRP was 3.8 mg/L (interquartile range: 1.3-10.2), without a significant difference between ST-segment elevation and non-ST-segment elevation myocardial infarction presentations (3.2 vs. 6.0 mg/L; P = 0.15). After mutual adjustment and adjustment for age, diabetes (adjusted odds ratio: 4.46; 95% confidence interval: 1.40-14.15; P = 0.011) and current smoking (adjusted odds ratio: 4.74; 95% confidence interval: 1.65-13.59; P = 0.004) remained associated with elevated hsCRP. CONCLUSIONS: Two-thirds of patients had hsCRP >2 mg/L at ACS presentation. Diabetes and smoking were independently associated with elevation. These findings quantify the proportion meeting an inflammatory trial entry criterion but do not establish persistent inflammation or support anti-inflammatory treatment. Prospective studies with serial measurements and clinical outcomes are needed to determine whether elevation persists and identifies modifiable risk.
No takes yet. Share an insight, caveat, or question.
Tsiamis et al. (2026) conducted an observational in Acute coronary syndrome (n=93). High-sensitivity C-reactive protein (hsCRP) >2 mg/L on arrival vs. hsCRP ≤2 mg/L was evaluated on Prevalence of elevated high-sensitivity C-reactive protein (>2 mg/L) at acute coronary syndrome presentation (OR 4.46, 95% CI 1.40-14.15, p=0.011). Elevated hsCRP occurred in 67.7% of ACS presentations, independently associated with diabetes and smoking.
Synapse has enriched 10 related papers. Consider them for comparative context: